We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Adverum Biotechnologies Inc | NASDAQ:ADVM | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.18 | 1.84% | 9.97 | 9.90 | 10.10 | 10.11 | 9.97 | 10.11 | 8,282 | 14:32:54 |
Delaware
|
001-36579
|
20-5258327
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a–12 under the Exchange Act
(17 CFR 240.14a–12)
|
☐
|
Pre-commencement communication pursuant to Rule 14d–2(b) under the
Exchange Act (17 CFR 240.14d–2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e–4(c) under
the Exchange Act (17 CFR 240.13e–4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock
|
ADVM
|
Nasdaq Global Market
|
Emerging growth company
|
☐
|
Proposal No. 1. |
Election of Directors: This was a contested election to
elect three directors to serve until the 2024 Annual Meeting of Stockholders. Adverum had nominated three directors and The Sonic Fund II, L.P. (“Sonic”) had nominated three directors.
|
Proposal No. 2. |
Ratification of Selection of Independent Registered Public Accounting Firm.
Adverum’s stockholders were asked to ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of Adverum for its fiscal year ending December 31, 2021.
|
Proposal No. 3. |
Advisory Approval of Executive Compensation. Adverum’s stockholders were
asked to approve, on an advisory basis, of the compensation of Adverum’s named executive officers, as disclosed in the proxy statement.
|
Votes
For
|
Votes
Withheld
|
|||
Dawn Svoronos
|
48,299,685
|
5,236,404
|
||
Reed V. Tuckson, M.D.
|
53,131,087
|
405,002
|
||
Thomas Woiwode, Ph.D.
|
53,148,231
|
387,858
|
Votes
For
|
Votes
Withheld
|
|||
Jean Bennett, M.D., Ph.D.
|
22,141,498
|
38,446
|
||
Jodi Cook, Ph.D.
|
22,132,266
|
47,678
|
||
Herbert Hughes
|
22,126,237
|
53,707
|
Votes For
|
Votes
Against
|
Abstentions
|
75,585,161
|
126,559
|
380,022
|
Votes For
|
Votes
Against
|
Abstentions
|
46,353,570
|
29,287,503
|
74,960
|
Adverum Biotechnologies, Inc.
|
||
Date: May 14, 2021
|
By:
|
/s/ Laurent Fischer, M.D.
|
Laurent Fischer, M.D.
|
||
Chief Executive Officer
|
1 Year Adverum Biotechnologies Chart |
1 Month Adverum Biotechnologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions